Envíe este artículo por correo electrónico Construcción de un cuestionario para la Valoración de los Efectos Subjetivos de Sustancias con Potencial de Abuso (VESSPA): Evaluación del éxtasis
Resumen
Se construye y valida un instrumento para medir los efectos subjetivos producidos por la 3,4-metilenodioximentanfetamina (MDMA). Tras la construcción de un banco de ítems, posteriores reducciones y un análisis factorial, se obtuvo un cuestionario de 36 ítems al que se le denominó VESSPA (Valoración de Efectos Subjetivos de Sustancia con Potencial de Abuso). El cuestionario consta de 6 escalas: “Sedación”, “Somatización Ansiosa”, “Cambios de Percepción”, “Placer y Contacto Social”, “Actividad y Energía” y escala de “Sintomatología Psicótica”. Respecto a la fiabilidad se obtuvo una consistencia interna entre 0.67 y 0.86, así como un índice de correlación del testretest entre 0.79 y 0.91, según la escala. En cuanto a la validez se aplicaron tres pruebas: correlaciones entre escalas del VESSPA y del ARCI (Addiction Research Center Inventory-49 item short form), puntuación de las diferentes escalas frente a otras condiciones simuladas (alcohol, cannabis, cocaína y LSD) y respuesta del cuestionario en situación experimental en un ensayo clínico en el que se administró MDMA y alcohol. Los resultados demuestran que el cuestionario VESSPA es un instrumento válido y fiable para medir los efectos farmacológicos de la MDMA y de otros psicofármacos, y puede ser utilizado también en ensayos clínicos.
Palabras clave
Referencias
Adams, G.S. (1975). Medición y evaluación. Barcelona: Herder.
Anastasi, A. (1982). Tests psicológicos (3ª edición). Madrid:
Aguilar.
Arasteh, K., Poudevida, S., Farré, M., Roset, P.N., Camí, J (1999). Response patterns of the Spanish version of the 49-item short form of the Addiction Reserch Center Inventory (ARCI) after the use of sedatives, stimulants, and opioids. Drug and Alcohol Dependence, 55, 117-125.
Brauer, L.H., Ambre, J. & de Wit, H. (1996). Acute tolerance
to subjective but not cardiovascular effects of d-amphetamine
in normal, healthy men. Journal of Clinical Psychopharmacology, 16, 72-76.
Brauer, L.H., Rukstails, M.R. & de Wit, H. (1995). Acute subjective responses to paroxetine in normal volunteers.
Drug and alcohol Dependence, 39, 223-230.
Burnat, P., Le Brumant-Payen, C., Huart, B., Ceppa, F. & Pailler,
F.M. (1996). L'ecstasy: psychostimulant, hallucinogène et toxique. La Presse Médicale, 25, 1208-1212.
Camí, J. y Farré, M. (1996). Éxtasis, la droga de la ruta del
bakalao. Medicina Clínica (Barcelona), 106, 711-716.
Camí, J., Farré, M., Mas, M., Roset, P.N., Poudevida, S., Mas, A., San, L. & de la Torre, R. (2000). Human Pharmacology of 3,4-Methylenedioxy-methamphetamie (“Ecstasy”): Psychomotor Performance and Subjective Effects. Journal of Clinical Psichopharmacology, 20, 455-466.
Claridge, G. (1994). LSD: A missed opportunity. Human Psychopharmacology, 9, 343-351.
Cohen, R.S. (1995). Subjective reports on the effects of the
MDMA (ecstasy) experience in humans. Progress in Neuropsychopharmcology and Biological Psychiatry, 19, 1137-1145.
Cohen, R.S. (1996). Adverse symptomatology and suicide
associated with the use of methylenedioxymethamphetamine
(MDMA, ecstasy). Biological Psychiatry, 39, 819-820.
Cone, E.J. & Johnson, R.E. (1988b). Marijuana-laced brownies:
Bejavioral effects, physiologic effects, and urinalysis in humans following ingestion. Journal of Analytical Toxicology, 12, 169-175.
Cone, E.J., Welch, P. & Lange, W.R. (1988a). Clonidine partially
blocks the physiologic effects but not the subjective effects produced by smoking marijuana in male human subjects. Pharmacology Biochemistry and Behaviour, 29, 649-652.
Creighton, F.J., Black, D.L. & Hyde, C.E. (1991). Ecstasy psychosis and flashbacks. British Journal of Psychiatry, 159, 713-715.
Curran, H.V. & Travill, R.A. (1997). Mood and cognitive effects of ±3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’): week-end ‘high’ followed by midweek low. Addiction, 92, 821-831.
Chait, L.D. (1992). Factors influencing the subjective response
to caffeine. Behavioural Pharmacology, 3, 219.
Chait, L.D. (1993). Factors influencing the reinforcing and
subjective effects of d-amphetamine in humans. Behavioural
Pharmacology, 4, 191-199.
Chait, L.D., Evans, S.M., Grant, K.A., Kamien, J.B., Johanson,
C.E. & Schuster, C.R. (1988). The discriminative stimulus and subjective effects of smoked marijuana in humans. Psychopharmacology, 94, 206-212.
Chait, L.D., Uhlenhuth, E.H. & Johanson, C.E. (1986). The
discriminative stimulus and subjective effects of phenylpropanolamine, mazindol and d-amphetamine in humans. Pharmacology Biochemistry and Behavior, 24, 1665-1672.
Davison, D. & Parrott, C. (1997). Ecstasy (MDMA) in recreational
users: self-reported psychological and physiological effects. Human Psychopharmacology, 12, 221-226.
de la Fuente, L., Rodríguez, M.A., Orta, J.V., Sánchez, J. y Barrio G. (1997). Epidemiología del consumo de drogas de diseño en España. Medicina Clínica (Barcelona), 108, 54-61.
Delegación del Gobierno para el Plan Nacional sobre Drogas
(1996, 1997, 1998, 1999, 2000 y 2001). Observatorio Español sobre Drogas. Informes nº1, 2, 3 y 4. Madrid: Ministerio del Interior.
Dowling, G.P., McDonough, E.T. & Bost, R.O. (1987). 'Eve'
and 'Ecstasy". A report of five deaths associated with the use of MDEA and MDMA. JAMA, 257, 1615-1617.
Downing, J. (1986). The psychological and physiological
effects of MDMA on normal volunteers. Journal of Psychoactive Drugs, 18, 335-340.
Farré, M., de la Torre, R., González, M.L., Terán, M.T., Roset,
P.N., Menoyo, E. & Camí, J. (1997). Cocaine and alcohol
interactions in humans: neuroendocrine effects and cocaethylene metabolism. Journal of Pharmacology and Experimental Therapeutics, 283, 164-176.
Farré, M., Roset, P.N., Hernández-López, C., Poudevida, S.,
Menoyo, E., de la Torre, R., Ortuño, J., Peiró, A. & Camí, J. (2001). Repeated adminstration of MDMA to healthy volunteers. Drug and Alcohol Dependence, 63, (Suppl. 1), S46.
Farré, M., Roset, P.N., Tomillero, A., Hernández-López, C.,
Poudevida, S., Menoyo, E., Sánchez, I., de la Torre, R., Ortuño, J. & Camí, J. (2000). Repeated administration of ecstasy to humans: preliminary findings. British Journal of Clinical Pharmacology, (Suppl. 49), 427.
Farré, M., Terán, M.T., & Camí, J. (1996). A comparison of the acute behavioral effects of flunitrazepam and triazolam in healthy volunteers. Psychopharmacology, 125, 1-12.
Ferrando, J. y Pérez J. (1996). Un instrumento para medir
quemazón profesional en los docentes: adaptación catalana del “Maslach Burnout Inventory (MBI)”. Revista de Psiquiatria de la Facultad de Medicina de Barcelona, 23, 11-18.
Fischman, M.W. & Foltin, R.W. (1991). Utility of subjectiveeffects
measurements in assessing abuse liability of drugs in humans. General methods of drug abuse liability assessment. British Journal of Addiction, 86, 1563-1570.
Fischman, M.W., Schuster, C.R., Resnekov, L., Shick, J.F.E.,
Krassnegor, N.A., Fennell, W. & Freedman, D.X. (1976). Cardiovascular and subjective effects of intravenous cocaine administration in humans. Archives of General Psychiatry, 33, 983-989.
Foltin, R.W., Fischman M.W., Pippen, P.A. & Kelly, T.H. (1993). Behavioral effects of cocaine alone and in combination with ethanol or marijuana in humans. Drug and Alcohol Dependence, 32, 93-106.
Greer, G., & Tolbert, R. (1986). Subjective reports of the
effects of MDMA in a Clinical Setting. Journal of Psychoactive
Drugs, 18, 319-327.
Grob, C.S., Poland, R.E., Chang, L. & Ernst, T. (1996). Psychobiologic effects of 3,4-methylenedioxymethamphetamine
in humans: methodological considerations and preliminary observations. Behavioural Brain Research, 73, 103-107.
Haertzen, C.A. (1966). Development of scales based on patterns
of drug effects, using the Addiction Research Center Inventory (ARCI). Psychological Reports, 18, 163-194.
Henry, J.A., Jefreys, K.J. y Dawling, S. (1993). Intoxicación y
muerte por 3,4-metilendioximetanfetamina (éxtasis). The Lancet (ed. española), 22, 3-7.
Hermle, L., Spitzer, M., Borchardt, D., Kovar, KA. & Gouzoulis,
E. (1993). Psychological effects of MDE in normal subjects. Are entactogens a new class of psychoactive agents?. Neuropsychopharmacology, 8, 171-176.
Hernández-López, C., Farré, M., Roset, PN., Menoyo, E., Pizarro, N., Ortuño, J., Torrens, M., Camí, J. & de la Torre, R. (2002). 3,4-Methylenedioxymethamphetamine (MDMA, Ecstasy) and Alcohol Interactions in Humans: Psychomotor Performance, Subjective Effects and Pharmacokinetics. Journal of Pharmacology and Experimental Therapeutics, 300, 236-244.
Higgins, S.T. & Stitzer, M.L. (1986). Acute marijuana effects
on social conversation. Psychopharmacology, 89, 234-238.
Holdstock, L. & de Wit, H. (1998). Individual differences in
the biphasic effects of ethanol. Alcoholism, Clinical and Experimental Research, 22, 1903-1911.
Holdstock, L. & de Wit, H. (1999). Individual differences in
subjective responses to ethanol and triazolam. Behavioral
Pharmacology, 10, 283-295.
Holzemer, W.L, Henry, S.B., Nokes, K.M., Corless, I.B., Brown, M.A., Powell-Cope, G.M., Turner, J.G. & Inouye, J. (1999). Validation of the sign and symptom chek-list for persons with HIV disease (SSC-HIV). Journal of advanced nursing, 30, 1041-1049.
Huckle, P., Palmer, D., Lester, H. & Huws, D. (1991). Case report: Ecstasy. The road to psychosis?. British Journal
of Clinical Psychiatry, 8, 4-5.
Isbell, H. & Logan, C.R. (1956). Studies on the Diethylamide
of Lysergic Acid (LSD-25): II. Effects of chlorpromazine, azacyclonol, and reserpine on the intensity of the LSDreactions.
Archives of Neurology and Psychiatry, 77, 350-358.
Isbell, H., Logan, C.R. & Miner, E.J. (1957). Studies on the
Diethylamide of Lysergic Acid (LSD-25): III. Attempts to attenuate the LSD-reaction in man by preteatment with neurohormanal blocking agents. Archives of Neurology and Psychiatry, 81, 20-27.
Jasinski, D. & Preston, K.L. (1986). Evaluation of mixtures of
morphine and d-amphetamine for subjective and physiological
effects. Drug and Alcohol Dependence, 17, 1-13.
Johanson, C.E. (1991). Discriminative stimulus effects of
diazepam in humans. Journal of the Experimental Analysis of Behavior, 257, 634-643.
Lamas, X., Farré, M., Llorente, M. & Camí, J. (1994). Spanish
version of the 49-item short form of the Addiction Research Center Inventory (ARCI). Drug and Alcohol Dependence, 35, 203-209.
Liester, M.B., Grob, C.S., Bravo, G.L. & Walsh, R.N. (1992).
Phenomenology and sequelae of 3,4 Methylenedioxymethamphetamina use. Journal of Nervous and
Mental Disease 180, 345-352.
Martin, W.R., Sloan, J.W., Sapira, J.D. & Jasinski, D.R. (1971). Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clinical Pharmacology and Therapeutics, 12, 245-258.
McCann, U. & Ricaurte, G.A. (1991). Lasting neuropsychiatric
sequelae of metylenedioximethamphetamine (Ecstasy) in recreational users. Journal of Clinical Psychopharmacology, 11, 302-305.
McCann, U. & Ricaurte, G.A. (1992). MDMA (Ecstasy) and
panic disorder. Biological Psychiatry, 32, 950-953.
McGuire, P., Cope, H. & Fahy, T. (1994). Diversity of psychopathology associated with use of 3,4 methylenedioxymethamphetamine ("ecstasy"). British Journal of
Psychiatry, 165, 391-395.
Nemeth-Coslett, R., Henningfield, J.E., O'Keeffe, M.K. & Giffiths, R.R. (1986). Effects of marijuana smoking on subjective ratings and tobacco smoking. Pharmacology Biochemistry and Behavior, 29, 649-652.
Nunnally, J.C. & Bernstein, I.H. (1994). Psychometric Theory
(3rd edition). New York: McGraw-Hill.
Observatorio Europeo de las Drogas y las Toxicomanías
(2000). Informe anual sobre el problema de la drogodependencia en la Unión Europea. Lisboa.
Pallanti, S. & Mazzi, D. (1992). MDMA (Ecstasy) precipitation
of panic disorder. Biological Psychiatry, 32, 91-95.
Parrot, A.C. & Stuart, M. (1997). Ecstasy (MDMA), amphetamine, and LSD: Comparative mood profiles in recreational polydrug users. Human Psychopharmacology,
, 501-504.
Pérez, J. y Torrubia, R. (1986). Fiabilidad y validez de la versión
española de la Escala de Búsqueda de Sensaciones (forma V). Revista Latinoamericana de Psicología, 18, 7-22.
Peroutka, S.J. (1990). Ecstasy: the clinical, pharmacological
and neurotoxicological effects of the drug MDMA. Dordrecht:
Kluwer.
Peroutka, S.J., Newman, H. & Harris, H. (1988). Subjective
effects of 3,4-Methylene-dioxymethamphetamina in recreational Users. Neuropsychopharmacology, 1, 273-277.
Poudevida, S., Farré, M., Mas, M. y Camí, J. (1999). Objetivar
lo subjetivo, de la fiesta al laboratorio. Ulises, 2, 33-38.
Poudevida, S., Farré, M., Mas, M., Roset, P.N. y Camí, J.
(1997). Elaboración de un instrumento para evaluar los efectos subjetivos producidos por el éxtasis en condiciones experimentales. IV Congreso de la Sociedad Española de Toxicomanías, Santander. Libro de resúmenes, 117.
Preston K.L., Sullivan J.T., Strain, E.C. & Bigelow, G.E. (1992). Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. Journal of Pharmacology and Experimental Therapeutics, 262, 279-291.
Renom, J., Solanas, A. y Puyuelo, M. (1995). Análisis psicométrico de una prueba de lenguaje y su adaptación
informática. Revista de logopedia, foniatría y audiología, 15, 121-137.
Riba, J., Rodríguez-Fornells, A., Urbano, G, Morte, A., Antonijoan, R., Montero, M., Callaway, J.C. & Barbanoj, M.J.
(2001a). Subjective effects and tolerability of the South American psichoactive beverage Ayahuasca in healthy volunteers. Psychopharmacology, 154, 85-95.
Riba, J., Rodríguez-Fornells, A., Strassman, R.J. & Barbanoj,
M.J. (2001b). Psychometric assessment of the Hallucinogen
Rating Scale. Drug and Alcohol Dependence, 62, 215-223.
Rush, C.R., Sullivan, J.T. & Griffiths, R.R. (1995). Intravenous
caffeine in stimulant drug abusers: Subjective reports and physiological effects. Journal of Pharmacology and Experimental Therapeutics, 273, 351-358.
Schifano, F. (1991) Chronic atypical psychosis associated
with MDMA (“ecstasy”) abuse. The Lancet, 338, 1335.
Series, H., Boeles, S., Dorkins, E. & Peveler, R. (1994). Psychiatric complications of ecstasy use. Journal of
Psychopharmacology, 8, 60-61.
Smith, L.F. (1999). The WOMB (Women's views of birth) antenatal satisfaction questionnaire: development, dimensions, internal reliability, and validity. British journal of general practice, 49, 971-975.
Solowij, N., Hall, W. & Lee, N. (1992). Recreational MDMA
use in Sydney: a profile of ‘Ecstasy’ users and their experiences with the drug. British Journal of Addiction, 87, 1161-1172.
Strassman, R.J., Qualls, C.R., Uhlenhuth, E.H. & Kellner, R. (1994). Dose-response study of N,N-dimethyltriptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Archives of General Psychiatry, 51, 98-108.
Tancer, M.E. & Johanson C.E. (2001). The subjective effects
of MDMA and mCPP in moderate MDMA users. Drug and Alcohol Dependence, 65, 97-101.
Tange, C. (1999). Construction of a scale of attitude toward
death in adolescence and its validity and reliability. Shinrigaku Kenkyu, 70, 327-332.
Terán, M.T., Farré, M., Lamas, X., Ugena, B. & Camí, J. (1993). Subjective and psychomotor effects of flunitrazepam in healthy volunteers. In: L. Harris (Ed.), Problems of Drug Dependence. NIDA Research Monograph, 132, 348.
Vollenweider, F.X., Gamma, A., Liechti, M. & Huber, T. (1998).
Psychological and cardiovascular effects and short-term sequelae of MDMA (“Ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology, 19, 241-251.
Warot, D., Danjau, P., Payan, C. & Puech, A.J. (1997). Sensitivity
and specificity to amphetamine of a French version of the 49-items short form of the Addiction Research Center Inventory. Drug and Alcohol Dependence, 45, 177-183.
Williamson, S., Gossop, M., Powis, B., Griffiths, P., Fountain,
J. & Strang, J (1997). Adverse effects of stimulant drugs in a community sample of drug users. Drug and Alcohol Dependence, 44, 87-94.
World Medical Association (1996). Declaration of Helsinki.
South Africa: Somerset West.
DOI: https://doi.org/10.20882/adicciones.435
Enlaces refback
- No hay ningún enlace refback.
